Tehran University of Medical Sciences

Science Communicator Platform

Stay connected! Follow us on X network (Twitter):
Share this content! On (X network) By
Covid Vaccine Recommendations in Dermatologic Patients on Immunosuppressive Agents: Lessons Learned From Pandemic Publisher Pubmed



Aryanian Z1, 2 ; Balighi K1, 3 ; Afshar ZM4, 5 ; Zamanian MH5 ; Razavi Z1, 3 ; Hatami P1
Authors
Show Affiliations
Authors Affiliations
  1. 1. Autoimmune Bullous Diseases Research Center, Tehran University of Medical Sciences, Tehran, Iran
  2. 2. Department of Dermatology, Babol University of Medical Sciences, Babol, Iran
  3. 3. Department of Dermatology, School of Medicine Razi Hospital, Tehran University of Medical Sciences, Tehran, Iran
  4. 4. Clinical Research Development Center, Imam Reza Hospital, Kermanshah University of Medical Sciences, Kermanshah, Iran
  5. 5. Department of Infectious Disease, School of Medicine, Imam Reza Hospital, Kermanshah University of Medical Sciences, Kermanshah, Iran

Source: Journal of Cosmetic Dermatology Published:2022


Abstract

Background: Since SARS-CoV2 vaccines were approved without enough long-term monitoring due to emergent situations, some issues have been raised about timing and protocol of receiving them by patients treated by different immunosuppressive agents. Aim and Method: Here, we present different aspects of SARS-CoV-2 vaccination in such patients in the field of dermatology. Result: In brief, SARS-CoV-2 vaccination is recommended in all dermatologic patients, regardless of their disorders and therapeutic regimens. Nevertheless, special considerations should be given to the immunosuppressive therapy and its association with vaccination timing due to the decreased immunogenicity of vaccines in this setting. Conclusion: Novel biologic immunotherapies are advantageous over conventional systemic therapies not only in their safety and selective functions but also in this aspect that many of them do not affect vaccines immunogenicity. © 2022 Wiley Periodicals LLC.